Every Form 4 that Solventum Corporation (SOLV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SOLV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SOLV filings page.
Solventum Corp (SOLV) reported that Chief Executive Officer and director Bryan C. Hanson settled 67,261 Restricted Stock Units into an equal number of shares of Common Stock on September 1, 2026. As part of the same event, 26,468 shares of Common Stock were delivered or withheld to cover the exercise price or tax liability at $90.95 per share, with the remaining shares retained as directly owned Common Stock. The RSUs used in this transaction were fully vested and, after settlement, no units from this grant remained outstanding.
Solventum Corp (symbol: SOLV) is the issuer of record for a Form 4 filing submitted to the SEC.
ALBAN CARLOS reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Carlos Alban received a grant of 3,300 Restricted Stock Units (RSUs). Each RSU represents the right to receive 1 share of Solventum common stock upon settlement, so this award covers 3,300 underlying shares. The RSUs were granted at no cash cost and will fully vest on May 15, 2027, if he continues serving through that date. Following this grant, Alban holds 3,300 RSUs directly, reflecting a routine, compensation-related equity award rather than an open-market share purchase or sale.
COX CARRIE SMITH reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Carrie Smith Cox received a grant of 4,848 Restricted Stock Units, each representing one share of common stock upon settlement. These RSUs were awarded at no cash cost and will fully vest on May 15, 2027, if her service continues through that date.
Solventum Corp director Susan D. DeVore received a grant of 3,300 Restricted Stock Units (RSUs) that convert into the same number of common shares upon settlement. The award was given at no cash cost to her and represents equity-based compensation rather than an open-market purchase.
The RSUs are scheduled to fully vest on May 15, 2027, provided she continues to serve through that date. Following this grant, her reported holdings in RSUs tied to common stock total 3,300 units, aligning her compensation more closely with future company performance.
Edwards Shirley Ann reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Shirley Ann Edwards received a grant of 3,300 Restricted Stock Units as equity compensation. Each RSU represents a right to receive one share of common stock upon settlement. The RSUs will fully vest on May 15, 2027, if she remains in service through that date.
EISENBERG GLENN A reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Glenn A. Eisenberg received a grant of 3,300 Restricted Stock Units, each representing a contingent right to one share of common stock upon settlement. These RSUs vest in full on May 15, 2027, subject to continued service, leaving him with 3,300 derivative units reported after this award.
Harris Bernard A Jr reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Harris Bernard A Jr received a grant of 3,300 Restricted Stock Units, each representing a right to receive one share of common stock upon settlement. These RSUs were awarded at no cash cost to him and will fully vest on May 15, 2027, if he continues in service through that date.
MAY KAREN J reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Karen J. May received a grant of 3,300 Restricted Stock Units (RSUs). These RSUs give her the right to receive 3,300 shares of Solventum common stock upon settlement. The award fully vests on May 15, 2027, subject to her continued service with the company, and represents her full reported RSU holdings after this grant.
Mily Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Mily Elizabeth received a grant of 3,300 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Solventum common stock upon settlement. The RSUs will fully vest on May 15, 2027, if she continues serving through that date.
Following this equity award, she holds 3,300 RSUs directly. This is a compensation-related grant rather than an open-market share purchase or sale.
WEILAND JOHN H reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director John H. Weiland received a grant of 3,300 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive 1 share of Solventum common stock upon settlement. The RSUs will fully vest on May 15, 2027, if he continues serving through that date.
Wendell Amy McBride reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Wendell Amy McBride received a grant of 3,300 restricted stock units as equity compensation. Each RSU represents a contingent right to receive 1 share of Solventum common stock upon settlement. The award vests in full on May 15, 2027, subject to continued service. Following this grant, McBride holds 3,300 RSUs directly.
Solventum Corp director Darryl L. Wilson received a grant of 3,300 Restricted Stock Units (RSUs). The award was made on May 15, 2026 and represents a compensation-related acquisition rather than an open‑market trade.
Each RSU represents a contingent right to receive 1 share of Solventum common stock upon settlement. The RSUs are scheduled to fully vest on May 15, 2027, provided Wilson continues to serve through that vesting date. Following this grant, his reported derivative holdings from this award total 3,300 RSUs.
Solventum Corp Chief Human Resources Officer Tammy L. Gomez exercised 3,960 Restricted Stock Units into Common Stock on May 13, 2026. To cover tax obligations, 1,668 shares were disposed of at $74.41 per share, leaving a net 2,292 new shares.
After these transactions, Gomez directly holds 13,362 shares of Common Stock. The related RSUs vest in three equal tranches on May 13, 2025, May 13, 2026, and May 13, 2027, subject to continued service.
Solventum Corp’s Chief Financial Officer Wayde D. McMillan exercised 9,503 Restricted Stock Units into an equal number of common shares on May 13, 2026. To satisfy tax obligations related to this vesting, 4,404 common shares were withheld at $74.41 per share. Following these transactions, he directly holds 48,637 shares of Solventum common stock. Each RSU represents a contingent right to receive one share of common stock and vests in three annual tranches, subject to continued service.
Solventum Corp Chief Supply Chain Officer Paul S. Harrington reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 13, 2026, he exercised RSUs to acquire 3,960 shares of Common Stock, with 1,678 shares withheld to cover tax obligations. Following these transactions, he held 20,452 Common Stock shares directly. The RSUs vest in three equal tranches on May 13, 2025, 2026, and 2027, subject to continued service.
Solventum Corp Chief Accounting Officer Mary T. Wilcox reported routine equity compensation activity. She exercised derivative awards covering 2,376 Restricted Stock Units into an equal number of Common Stock shares on May 13, 2026. To cover tax obligations, 728 Common Stock shares were disposed of through a tax-withholding transaction, rather than an open-market sale.
Following these transactions, Wilcox directly holds 6,904 shares of Common Stock and 2,377 Restricted Stock Units. The RSUs are scheduled to vest in three equal tranches on May 13, 2025, May 13, 2026, and May 13, 2027, subject to continued service through each vesting date.
Solventum Corp’s Chief Legal Affairs Officer, Marcela A. Kirberger, reported routine equity compensation activity involving Restricted Stock Units (RSUs) and related tax withholding. She exercised 4,488 RSUs, each converting into one share of common stock at a stated price of $0.00 per share.
To cover tax obligations, 1,952 common shares were disposed of at $74.41 per share as a tax-withholding transaction, not an open-market sale. Following the tax-withholding entry, the Form 4 shows 13,540 common shares reported as directly held.
Solventum Corp Chief Executive Officer Bryan C. Hanson reported routine equity compensation transactions involving company stock. He exercised Restricted Stock Units covering 34,315 shares of Common Stock, increasing his direct holdings. To cover tax obligations, 13,503 shares of Common Stock were disposed of at a price of $74.41 per share through share withholding, not an open-market sale. After these transactions, he directly holds 144,722 shares of Common Stock and 34,316 Restricted Stock Units that continue to vest over time.
Solventum Corp Chief Information Officer Amy Landucci reported routine equity compensation activity involving restricted stock units and related tax withholding. She exercised RSUs to acquire 4,422 shares of Solventum common stock. To cover tax obligations, 2,017 shares were withheld and delivered back as a tax-withholding disposition at $74.41 per share.
After these transactions, Landucci directly owns 39,888 shares of Solventum common stock. The RSUs referenced in the footnotes vest in three equal annual tranches on May 13, 2025, May 13, 2026 and May 13, 2027, contingent on continued service.
Solventum Corp director Wendell Amy McBride exercised restricted stock units into common shares. On April 30, 2026, 3,403 Restricted Stock Units (RSUs), each representing a contingent right to receive 1 share of common stock, were settled into 3,403 shares of common stock at a stated price of $0.00 per share.
Following this exercise, McBride directly holds 10,422 shares of Solventum common stock, and the RSU balance related to this grant is now shown as 0 units. The footnotes state that the RSUs involved were fully vested before settlement.
Solventum Corp director John H. Weiland exercised 3,403 Restricted Stock Units into 3,403 shares of Common Stock on April 30, 2026. The RSUs were fully vested and carried a conversion price of $0.00 per unit, giving him common shares without a cash outlay.
After this settlement, Weiland directly holds 8,947 shares of Common Stock and no remaining RSUs from this grant. This filing reflects a compensation-related derivative exercise rather than an open-market purchase or sale.
Solventum Corp director Mily Elizabeth exercised restricted stock units into common shares. On April 30, 2026, 3,403 Restricted Stock Units were converted into 3,403 shares of Solventum common stock at a stated price of $0.00 per share, reflecting a compensation-related equity settlement rather than a market purchase.
Following this exercise, Elizabeth directly held 9,009 shares of Solventum common stock. The RSUs referenced were fully vested and each RSU represented a contingent right to receive one share of common stock upon settlement. The filing shows no open-market sales or tax-withholding dispositions linked to this transaction.
Solventum Corp director Wilson Darryl L. exercised fully vested restricted stock units to receive 3,403 shares of Common Stock on April 30, 2026. The RSUs represented a contingent right to receive one share of common stock per unit upon settlement.
After this non-cash derivative exercise, he directly holds 8,947 shares of Solventum common stock. No open-market purchases or sales were reported in this filing.
Solventum Corp director Karen J. May exercised 3,403 Restricted Stock Units into Common Stock. Each RSU converted into 1 share of Solventum Common Stock at a stated price of $0.00 per unit.
Following the transaction, she directly holds 8,947 shares of Common Stock, and the exercised RSUs are now fully settled. The filing shows an option-style conversion but no open-market sale or purchase of shares.
Solventum Corp director Harris Bernard A Jr exercised previously granted Restricted Stock Units (RSUs) into common stock. He acquired 3,403 shares of Solventum common stock through the conversion of fully vested RSUs, and now directly holds 8,947 common shares in total. No shares were sold in this filing.
Solventum Corp director Glenn A. Eisenberg reported a routine equity compensation event. On April 30, 2026, he exercised fully vested Restricted Stock Units (RSUs) covering 3,403 shares of Common Stock, converting them into directly held shares.
Following this settlement, Eisenberg directly holds 8,947 shares of Solventum Common Stock. The RSUs represented a contingent right to receive one share of Common Stock per unit upon settlement, and all such RSUs referenced in this filing are now fully settled, with no remaining RSU balance shown.
Solventum Corp director Shirley Ann Edwards exercised 3,403 restricted stock units into 3,403 shares of Common Stock. The RSUs were fully vested and converted at a stated price of $0.00 per share. Following the transaction, she directly holds 8,947 shares of Solventum Common Stock. No open-market purchases or sales were reported; this reflects a compensation-related derivative exercise.
Solventum Corp director Susan D. DeVore exercised restricted stock units into common shares. On April 30, 2026, she converted 3,403 RSUs, receiving the same number of Solventum common shares. Following this transaction, she directly holds 8,947 shares of common stock. The RSUs were fully vested and represented a right to receive one share of common stock per unit.
Solventum Corp director Carrie Smith Cox exercised 4,916 restricted stock units into Common Stock. The filing shows these Restricted Stock Units, each representing one share of Common Stock upon settlement, were fully vested and converted at a price of $0.00 per unit.
Following this compensation-related exercise, Cox directly holds 16,400 shares of Solventum Common Stock. The transaction involves a derivative exercise rather than an open-market purchase or sale, so it does not reflect new cash trading activity in the company’s shares.
Solventum Corp director Carlos Alban exercised restricted stock units into common shares. On April 30, 2026, he converted 3,403 Restricted Stock Units, each representing one share of common stock, into 3,403 shares of Solventum common stock in a non-cash transaction at a stated price of $0.00 per unit.
The filing notes these RSUs were fully vested prior to settlement. After the exercise, Alban directly holds 8,947 shares of Solventum common stock. No open-market purchases or sales and no tax-withholding dispositions are reported in this filing, indicating a routine compensation-related equity settlement.
Solventum Corp’s Chief Accounting Officer, Mary T. Wilcox, exercised previously granted restricted stock units into common shares. On March 27, 2026, she converted 5,199 RSUs, receiving an equal number of common shares. A portion of these shares was then withheld to cover tax obligations.
Of the acquired shares, 1,591 common shares were disposed of through tax withholding at a price of $62.76 per share, leaving Wilcox with 5,256 common shares held directly after the transactions. The RSUs were fully vested at the time of exercise, indicating this was a routine compensation-related event rather than an open-market trade.
Solventum Corp director Carrie Smith Cox exercised restricted stock units into common shares. On March 27, 2026, she exercised 6,336 Restricted Stock Units, each representing one share of common stock upon settlement. Following the exercise, she directly holds 11,484 shares of Solventum common stock. The filing states the RSUs were fully vested at the time of exercise.
Solventum Corp director Susan D. DeVore exercised fully vested Restricted Stock Units to receive Common Stock as equity compensation. She converted 1,980 RSUs, each representing a contingent right to one share of Common Stock, into 1,980 shares at an exercise price of $0.00 per share.
After the transaction, she directly holds 5,544 shares of Solventum Common Stock. The filing shows a routine derivative exercise/conversion with no open‑market buying or selling activity.
Solventum Corp director Shirley Ann Edwards exercised restricted stock units into common shares. On March 27, 2026, she converted 1,980 Restricted Stock Units, each representing a right to receive one share of common stock when settled. This derivative exercise resulted in 1,980 shares of Solventum common stock credited to her direct holdings.
Following the transaction, Edwards directly holds 5,544 shares of Solventum common stock. The filing describes this as an exercise or conversion of a derivative security, not an open-market purchase or sale, and the RSUs involved were reported as fully vested.
Solventum Corp director Glenn A. Eisenberg exercised equity awards to increase his direct share ownership. He converted 1,980 fully vested Restricted Stock Units into 1,980 shares of Common Stock at no exercise price. Following the transaction, he directly holds 5,544 Solventum common shares. This was an option/RSU exercise, not an open-market purchase or sale.
Solventum Corp director Harris Bernard A Jr exercised previously granted Restricted Stock Units, converting 1,980 RSUs into 1,980 shares of Common Stock at a stated price of $0.00 per share. Following this vesting and settlement event, he now directly holds 5,544 shares of Solventum Common Stock. The RSUs were fully vested before settlement, meaning the shares were delivered as part of his existing equity compensation rather than through an open-market purchase or sale.
Solventum Corp director Wilson Darryl L. exercised restricted stock units into common shares. He converted 1,980 Restricted Stock Units into 1,980 shares of Common Stock at a stated price of $0.00 per share, reflecting settlement of fully vested RSUs. Following the transaction, he directly holds 5,544 shares of Solventum common stock.
Solventum Corp director Wendell Amy McBride exercised fully vested Restricted Stock Units into common stock. McBride converted 1,980 RSUs, each representing one share of common stock, at an exercise price of $0.00 per unit. Following the transaction, McBride directly holds 7,019 shares of Solventum common stock. This filing reflects a compensation-related derivative exercise rather than an open-market purchase or sale.
Solventum Corp director John H. Weiland exercised equity awards rather than trading in the open market. On March 27, 2026, he exercised 1,980 Restricted Stock Units, each converting into one share of Solventum common stock at a stated price of $0.00 per share.
Following this RSU settlement, Weiland now directly holds 5,544 shares of Solventum common stock. The filing shows no open-market purchases or sales, only the conversion of fully vested RSUs into common shares as part of his equity compensation.
Solventum Corp director Mily Elizabeth exercised fully vested restricted stock units to receive common shares. On March 27, 2026, she exercised 1,980 RSUs, each representing one share of common stock, at an exercise price of $0.00 per unit.
Following the conversion, she directly holds 5,606 shares of Solventum common stock. The RSU award is now fully settled with no RSUs remaining outstanding from this grant, and there were no open-market purchases or sales reported in this filing.
Solventum Corp director Carlos Alban exercised restricted stock units to receive common shares. On this date, he converted 1,980 fully vested RSUs into 1,980 shares of Solventum common stock at an exercise price of $0.00 per unit. After the transaction, he holds 5,544 common shares directly.
Solventum Corp director Karen J. May exercised restricted stock units to acquire additional shares of common stock. On this date, 1,980 RSUs converted into 1,980 shares of common stock at a stated price of $0.00 per share. Each RSU represented a right to receive one share upon settlement, and the RSUs were fully vested. Following the transaction, May directly holds 5,544 shares of Solventum common stock, reflecting an exercise-and-hold move with no shares sold in this filing.
Solventum Corp director Wendell Amy McBride bought 1,475 shares of Common Stock in an open-market purchase. The transaction took place on 2026-03-10 at an average price of $68.03 per share. Following this transaction, her direct holdings increased to 5,039 shares of Solventum common stock.
Solventum Corp Chief Information Officer Amy Landucci reported equity compensation activity involving restricted stock units and common shares. On March 5, 2026, she was granted 12,716 Restricted Stock Units (RSUs), each representing a right to receive one share of Class A common stock upon settlement, vesting in three equal annual installments.
On March 6, 2026, 3,795 RSUs were converted into 3,795 shares of common stock, and 1,731 common shares at $69.41 per share were disposed of to cover tax obligations, described as a tax-withholding disposition. After these transactions, her directly held common stock position was 37,483 shares, with 7,593 RSUs remaining from the earlier award.
Solventum Corp Chief Supply Chain Officer Paul S. Harrington reported equity compensation activity and related tax withholding. On March 5, 2026, he was granted 10,950 Restricted Stock Units (RSUs), each representing a right to receive one share of Class A common stock. These RSUs vest in three equal annual tranches on the first, second and third anniversaries of the grant date, subject to continued service. On March 6, 2026, 3,300 RSUs were exercised for 3,300 shares of common stock at a stated price of $0.00, and 1,073 shares of common stock were disposed of at $69.41 per share to cover tax obligations, leaving 18,170 common shares held directly.
Solventum Corp Chief Financial Officer Wayde D. McMillan reported several equity-related transactions. On March 5, 2026, he acquired 35,321 Restricted Stock Units (RSUs) as a grant, each representing a right to receive 1 share of Class A Common Stock. These RSUs vest in three equal annual tranches on the first, second and third anniversaries of the grant date, subject to continued service.
On March 6, 2026, he exercised 8,802 RSUs, converting them into 8,802 shares of Common Stock at a stated price of $0.00 per share. The filing also shows a disposition of 2,786 shares of Common Stock at $69.41 per share in a tax-withholding transaction to satisfy obligations arising from the equity award. After these transactions, his directly held Common Stock position was 43,538 shares, and his directly held RSUs totaled 35,321 units.
Solventum Corp Chief Human Resources Officer Tammy L. Gomez reported multiple equity compensation transactions. On March 5, 2026, she received a grant of 12,716 Restricted Stock Units (RSUs), each representing one share of Class A Common Stock. These RSUs vest in three equal annual installments on the first, second, and third anniversaries of the grant date, subject to continued service.
On March 6, 2026, 3,300 RSUs were exercised and converted into 3,300 shares of Common Stock at no cost, increasing her directly held Common Stock before withholding. To cover tax obligations, 895 Common shares were withheld at $69.41 per share, leaving her with 11,070 shares of Common Stock held directly after these transactions, and 6,603 RSUs remaining from earlier awards plus the new 12,716‑unit grant.
Solventum Corp Chief Executive Officer Bryan C. Hanson reported multiple equity transactions. On March 5, 2026, he acquired 105,963 Restricted Stock Units (RSUs), each representing a contingent right to one share of Class A common stock.
On March 6, 2026, he exercised RSUs covering 31,907 RSUs, receiving 31,907 shares of common stock, and then disposed of 10,395 shares of common stock at $69.41 per share to cover tax withholding. After these transactions, he directly held 123,910 shares of common stock and 105,963 RSUs. The new RSU grant vests in three equal annual tranches, subject to continued service.
Knight Heather reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp reported that Chief Commercial Officer Heather Knight received a grant of 31,789 Restricted Stock Units (RSUs) on March 5, 2026. Each RSU represents a contingent right to receive one share of Solventum’s Class A common stock upon settlement.
The RSUs vest in three equal tranches, with one-third vesting on each of the first, second, and third anniversaries of the grant date, conditioned on Ms. Knight’s continued service through each vesting date. Following this grant, she directly holds 31,789 RSUs.